ZURA vs. RLAY, SRRK, PRME, RGNX, CRGX, ITOS, HLVX, VALN, TSHA, and KYTX
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Relay Therapeutics (RLAY), Scholar Rock (SRRK), Prime Medicine (PRME), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), iTeos Therapeutics (ITOS), HilleVax (HLVX), Valneva (VALN), Taysha Gene Therapies (TSHA), and Kyverna Therapeutics (KYTX). These companies are all part of the "biological products, except diagnostic" industry.
Zura Bio (NASDAQ:ZURA) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
Zura Bio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Zura Bio has a net margin of 0.00% compared to Relay Therapeutics' net margin of -1,263.49%. Relay Therapeutics' return on equity of -42.66% beat Zura Bio's return on equity.
Zura Bio has higher earnings, but lower revenue than Relay Therapeutics.
Zura Bio currently has a consensus price target of $18.83, indicating a potential upside of 258.73%. Relay Therapeutics has a consensus price target of $22.20, indicating a potential upside of 246.33%. Given Zura Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than Relay Therapeutics.
In the previous week, Zura Bio had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 7 mentions for Zura Bio and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Zura Bio's score of 0.67 indicating that Relay Therapeutics is being referred to more favorably in the news media.
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 15.8% of Zura Bio shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Relay Therapeutics received 28 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Summary
Zura Bio and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
